• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

    2/14/24 12:50:09 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNDX alert in real time by email
    SC 13G 1 sndx_21424.htm KYNAM CAPITAL MANAGEMENT, LP sndx_21424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    Syndax Pharmaceuticals Inc
    (Name of Issuer)
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    87164F105
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 87164F105
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3660072
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    5,660,000
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    5,660,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    5,660,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.67%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 87164F105
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management GP, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3678691
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    5,660,000
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    5,660,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    5,660,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.67%
    12
    TYPE OF REPORTING PERSON
    OO
    CUSIP No.: 87164F105
           
    1
    NAME OF REPORTING PERSON
    Yue Tang
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    5,660,000
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    5,660,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    5,660,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.67%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 87164F105
    ITEM 1(a). NAME OF ISSUER:
    Syndax Pharmaceuticals Inc
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    35 Gatehouse Drive, Building D, Floor 3
    Waltham, MA USA
    02451
    ITEM 2(a). NAME OF PERSON FILING:
    Kynam Capital Management, LP
    Kynam Capital Management GP, LLC
    Yue Tang
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    221 Elm Road. Princeton, NJ 08540
    ITEM 2(c). CITIZENSHIP:
    Delaware
    Delaware
    U.S.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock, par value $0.0001 per share
    ITEM 2(e). CUSIP NUMBER:
    87164F105
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    5,660,000
    (b) Percent of class:
    6.67%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (ii) shared power to vote or to direct the vote:
    Kynam Capital Management, LP : 5,660,000

    Kynam Capital Management GP, LLC : 5,660,000

    Yue Tang : 5,660,000
    (iii) sole power to dispose or direct the disposition of:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (iv) shared power to dispose or to direct the disposition of:
    Kynam Capital Management, LP : 5,660,000

    Kynam Capital Management GP, LLC : 5,660,000

    Yue Tang : 5,660,000
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 87164F105
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 14 2024
    Kynam Capital Management, LP By: Kynam Capital Management GP, LLC, its General Partner
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    February 14 2024
    Kynam Capital Management GP, LLC
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    February 14 2024
    Yue Tang
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $SNDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNDX

    DatePrice TargetRatingAnalyst
    10/24/2024$37.00Buy
    UBS
    6/28/2024$37.00Buy
    Jefferies
    1/31/2024$36.00 → $23.00Sector Outperform → Sector Perform
    Scotiabank
    12/22/2023$45.00Buy
    Mizuho
    10/25/2023$29.00Buy
    BofA Securities
    10/11/2023$30.00Buy
    Goldman
    7/27/2023Sector Outperform
    Scotiabank
    7/11/2023$40.00Buy
    Guggenheim
    More analyst ratings

    $SNDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:04:07 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:03:03 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:02:03 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:04:07 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:03:03 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:02:03 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

      - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa

      5/12/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

      6/10/24 7:30:00 AM ET
      $PYXS
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

      WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo

      5/15/24 4:05:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

      – Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial – NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple abstracts showcasing clinical data for Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) were accepted for presentation at the 30th European Hematology Associatio

      5/14/25 9:30:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

      - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa

      5/12/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Participation in May Investor Conferences

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m. PT/ 12:20 p.m. ET.TD Cowen 6th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 28, 2025, at 10:30 a.m. ET. A live webcast of the fireside chats will be available in the Investor section o

      5/8/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    SEC Filings

    See more
    • Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      5/16/25 4:15:09 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

      SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      5/9/25 12:34:37 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

      SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      5/7/25 11:25:22 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      11/8/24 10:52:38 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      10/18/24 11:49:10 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

      SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      2/14/24 12:50:09 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SNDX
    Financials

    Live finance-specific insights

    See more

    $SNDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • UBS initiated coverage on Syndax Pharmaceuticals with a new price target

      UBS initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00

      10/24/24 6:28:31 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Syndax Pharmaceuticals with a new price target

      Jefferies initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00

      6/28/24 8:13:58 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals downgraded by Scotiabank with a new price target

      Scotiabank downgraded Syndax Pharmaceuticals from Sector Outperform to Sector Perform and set a new price target of $23.00 from $36.00 previously

      1/31/24 7:22:33 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

      – $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda

      5/5/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alt

      4/28/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan

      3/3/25 7:01:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

      Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

      11/18/24 9:22:42 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care